{"prompt": "['of health: mobility, ability to self-care, ability to undertake usual activities, pain / discomfort,', 'and anxiety / depression. The EQ-5D-5L also assesses current overall health. The goal of', 'measuring EQ-5D-5L is to assess the impact of treatment with emicizumab over time on', 'overall health and the different health dimensions. Data from the EQ-5D-5L can also be used', 'to inform pharmacoeconomic evaluations.', 'The study will also evaluate patient preference for treatment (EmiPref). Previous studies', 'have noted that patients express preference for treatments that do not have negative effects', '(e.g., pain that results from infusions), are not time-consuming, are not associated with high', 'treatment burden, and have a goal of achieving a \"normal life\" (Cimino et al. 2014). The', 'inclusion of a fit-for-purpose preference survey after the completion of 3 months of', 'emicizumab treatment will provide information on whether SC emicizumab is preferred to the', 'previous treatment and explore the potential underlying reasons for any findings. This', 'assessment will be performed after 3 months as the patients will have gained sufficient', 'experience with emicizumab and SC injection, while still being reliably able to recall their', 'experience with their prior therapy.', '4.', 'MATERIALS AND METHODS', '4.1', 'PATIENTS', 'This global study will enroll approximately 200 patients with congenital hemophilia A who', 'have persistent inhibitors against FVIII at enrollment. The patients are expected to be enrolled', 'at approximately 85 sites globally.', '4.1.1', 'Inclusion Criteria', 'Patients must meet the following criteria for study entry:', '1. Signed Informed Consent Form', \"2. As per the investigator's judgement, a willingness and ability to comply with scheduled\", 'visits, treatment plans, laboratory tests, and other study procedures, including the PRO', 'questionnaires and bleed diaries through the use of an electronic device or paper', '3. Aged 12 years or older at the time of informed consent', '4. Diagnosis of congenital hemophilia A with persistent inhibitors against FVIII', '5. Documented treatment with bypassing agents or FVIII concentrates in the last 6 months', '(on-demand or prophylaxis). Prophylaxis needs to be discontinued the latest by a day', 'before starting emicizumab.', '6. Adequate hematologic function, defined as platelet count 100,000/L and hemoglobin', '8 g/dL (= 4.97 mmol/L) at the time of screening', '7. Adequate hepatic function, defined as total bilirubin < 1.5 x the upper limit of normal', \"(ULN) (excluding Gilbert's syndrome) and aspartate aminotransferase (AST) and alanine\", 'aminotransferase (ALT) 3 xULN at the time of screening; no clinical signs or known', 'laboratory/radiographic evidence consistent with cirrhosis', '8. Adequate renal function, defined as serum creatinine 2.5 x ULN and creatinine', 'clearance by Cockcroft-Gault formula 30 mL/min', 'Emicizumab - F. Hoffmann-La Roche Ltd', '109 / Protocol MO39129, Version 3']['9. For women of childbearing potential: agreement to remain abstinent (refrain from', 'heterosexual intercourse) or use a highly effective contraceptive method with a failure', 'rate of < 1% per year during the treatment period and for at least five elimination half-', 'lives (24 weeks) after the last dose of emicizumab:', 'A woman is considered to be of childbearing potential if she is postmenarcheal, has', 'not reached a postmenopausal state (12 continuous months of amenorrhea with', 'no identified cause other than menopause), and has not undergone surgical', 'sterilization (removal of ovaries and/or uterus)', 'Examples of highly effective contraceptive methods with a failure rate of < 1% per', 'year include proper use of combined oral or injected hormonal contraceptives,', 'bilateral tubal ligation, male sterilization, hormone-releasing intrauterine devices,', 'and copper intrauterine devices. Alternatively, two methods (e.g., two barrier', 'methods such as a condom and a cervical cap) may be combined to achieve a', 'failure rate of < 1% per year. Barrier methods must always be supplemented with', 'the use of a non-lipid-based spermicide', 'The reliability of sexual abstinence should be evaluated in relation to the duration of', 'the clinical trial and the preferred and usual lifestyle of the patient. Periodic', 'abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods)', 'and withdrawal are not acceptable methods of contraception.', '4.1.2', 'Exclusion Criteria', 'Patients who meet any of the following criteria will be excluded from study entry:', '1. Inherited or acquired bleeding disorder other than hemophilia A', '2. Ongoing (or plan to receive during the study) ITI therapy (prophylaxis regimens with FVIII', 'and/or bypassing agents must be discontinued prior to enrollment). Patients receiving ITI', 'therapy will be eligible following the completion of a 72-hour washout period prior to the', 'first emicizumab administration', '3. History of illicit drug or alcohol abuse within 12 months prior to screening, as per the', \"investigator's judgment\", '4.', 'High risk for TMA (e.g., have a previous medical or family history of TMA), as per the', \"investigator's judgment\", '5. Previous (in the past 12 months) or current treatment for thromboembolic disease (with', 'the exception of previous catheter-associated thrombosis for which antithrombotic', 'treatment is not currently ongoing) or current signs of thromboembolic disease', '6.', 'Other conditions (e.g., certain autoimmune diseases) that may increase the risk of', 'bleeding or thrombosis', '7.', 'History of clinically significant hypersensitivity reaction associated with monoclonal', 'antibody therapies or components of the emicizumab injection', '8.', 'Known human immunodeficiency virus (HIV) infection with CD4 count < 200 cells/L', 'within 6 months prior to screening', '9. Use of systemic immunomodulators (e.g., interferon or rituximab) at enrollment or', 'planned use during the study, with the exception of antiretroviral therapy', 'Emicizumab - F. Hoffmann-La Roche Ltd', '110 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}